Terms: = Gastric cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Clinical Outcome
2 results:
1. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract] [Full Text] [Related]
2. Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer.
Shin SJ; Jeung HC; Ahn JB; Rha SY; Yoo NC; Roh JK; Noh SH; Chung HC
Cancer Lett; 2008 Nov; 270(2):269-76. PubMed ID: 18555590
[TBL] [Abstract] [Full Text] [Related]
